<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01030406</url>
  </required_header>
  <id_info>
    <org_study_id>AP-ADF-114</org_study_id>
    <nct_id>NCT01030406</nct_id>
  </id_info>
  <brief_title>Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Assess the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acura Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King Pharmaceuticals is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Acura Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the relative abuse potential of two
      different doses of orally administered Acurox Tablets to orally administered
      immediate-release (IR) oxycodone HCl tablets in non-dependent recreational opioid users.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug Liking/Disliking analyzed over 0-3 hours</measure>
    <time_frame>collected at 0.5,1,1.5, 2,3,4,5,6,8, and 12 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Take Drug Again Assessment (TDAA)</measure>
    <time_frame>1, 2, and 8 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment of Overall Drug Liking</measure>
    <time_frame>12 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupillometry</measure>
    <time_frame>pre-dose and 0.5,1,1.5,2,3,4,5,6,8, and 12 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Opioid Abuse</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment E</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug A</intervention_name>
    <description>Tablets</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug B</intervention_name>
    <description>Tablets</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug C</intervention_name>
    <description>Tablets</description>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug D</intervention_name>
    <description>Tablets</description>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets</description>
    <arm_group_label>Treatment E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is male or female between 18 and 55 years old.

          -  Subject is in generally good health, including no history of pulmonary disease, and
             has a body mass index (BMI) within 18-33 kg/m2.

          -  Subject is a recreational opioid user (i.e., at least 10 occasions within the past 12
             months, and at least 1 within the past 12 weeks) who is NOT physically dependent on
             opioids (per Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition-Text
             Revision [DSM-IV-TR]); is able to speak, read, and understand English; and will
             provide written informed consent.

          -  Subject has a minimum of a 6th grade reading level as determined by the Investigator
             or by the Rapid Estimation of Adult Literacy in Medicine (REALM).

        Exclusion Criteria:

          -  History or current diagnosis of substance dependence (except nicotine and caffeine)
             and/or alcohol abuse according to the criteria of DSM-IV-TR.

          -  History or current diagnosis of neurological, hepatic, renal, endocrine,
             cardiovascular, gastrointestinal, hematologic, pulmonary, or metabolic disease.

          -  Known allergy or history of hypersensitivity to oxycodone HCl, other opioids, or any
             component of Acurox Tablets.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lifetree Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2009</study_first_submitted>
  <study_first_submitted_qc>December 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2009</study_first_posted>
  <last_update_submitted>March 8, 2010</last_update_submitted>
  <last_update_submitted_qc>March 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Andy Reddick, CEO</name_title>
    <organization>Acura Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>Abuse Liability</keyword>
  <keyword>Abuse Prevention</keyword>
  <keyword>Abuse Resistance</keyword>
  <keyword>Abuse Deterrence</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

